The 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) is being held January 8–10, 2026, at Moscone West in San Francisco, California, with both in-person and online participation available for the global GI oncology community.
Building on its reputation as a premier forum for gastrointestinal cancer research and clinical progress, ASCO GI 2026 convenes medical oncologists, surgeons, radiation oncologists, gastroenterologists, pathologists, radiologists, researchers, trainees, and patient advocates to spotlight advances spanning translational science, precision therapies, and multidisciplinary care.
Across scientific sessions, educational programming, and featured abstract presentations, the meeting highlights emerging data and practical insights across the spectrum of GI malignancies supporting timely knowledge-sharing and broad accessibility through its hybrid format.
15 Posts Not To Miss From ASCO GI
“I love this and so envious that Kimryn Rathmell can execute this with her leadership role at OSUCCC to improve clinical trial access especially for rare cancers. I would love to see more cancer centers emulate this approach and provide this type of infrastructure.”
“An absolutely damning indictment of the costs of care (in the fiscal meaning of the word): just as many patients fear financial toxicity as death! ”
“Scoop de l’ASCO GI 2026
CT + zanidatamab + tislelizumab better than CT + trastuzumab in HER2+ gastric adenocarcinomas…and CT zanidatamab better than CT + trastuzumab (even if différence in OS did not reach yet statistical significance).”
“Phase 1/2 ReFocus data for lirafugratinib in FGFRi-naïve FGFR2+ CCA : ORR 47% (IRC) mDOR 11.8 mo (76% ≥6 mo) mPFS 11.3 mo mOS 22.8 mo DCR 96.5% Manageable on-target toxicity, but DR high. Oral GI26 by HollebecqueA
this Friday, delighted to contribute from Australia.”
“The HERIZON looks bright for HER2+ #UGI cancers! Improved OS with Zani + chemo + Tis! Congrats Dr. Elimova (the ONLY female at the podium during these orals PamelaKunzMD
Aparna Raj)!
“GI26
NEOSUMMIT-01, now presented
Randomized Ph II perioperative oxaliplatin-based doublet (CAPEOX or SOX) ± PD-1 inhibitor toripalimab in cT3–4N+ GC/GEJC.
For context: perioperative chemotherapy alone has produced only modest gains for decades, with relapse (especially peritoneal) remaining the dominant failure pattern.
NEOSUMMIT-01 delivers something we have not seen before
3-year EFS 74.7% vs 56.2%, HR 0.51, P=0.044
3-year OS 81.3% vs 72.2%, HR 0.45, P=0.036
Metastasis/relapse nearly cut in half: 18.5% vs 38.9%, P=0.019
mEFS not reached with perioperative chemoIO vs 38.2 months with chemo alone
Benefits held up in per-protocol analyses and after excluding dMMR patients.
The dramatic reduction in peritoneal relapse is the standout.
CAVEAT: China only study. Unclear if results will translate to a global population.
These are fantastic results and set a high bar for perioperative chemoIO in locally advanced GC/GEJC.”
AI in oncology isn’t about bigger models. It’s about better grounding.
At GI26, we showed that a guideline-anchored RAG model restricted to NCCN GI guidelines outperformed both baseline GPT-4 and broad literature-retrieval LLMs, with higher guideline concordance and fewer hallucinations.
Source of truth matters. Congrats to Connor Yost and our other co-authors, more to follow!!
Proving the point that partnerships like OpenEvidence + National Comprehensive Cancer Network® (NCCN®) | American Society of Clinical Oncology (ASCO) + Google Cloud bring much better results for highly specialized care.
📄 J Clin Oncol 2026 (Suppl 2; Abstr 805)
https://lnkd.in/e3AMiZpP ”
“Spending time with colleagues in GI Oncology Drs. Howard Safran, Rimini Breakstone, and Alex Raufi at The Warren Alpert Medical School of Brown University Brown University Health Legorreta Cancer Center at GI26.”
“Here is a great trial already in progress building off MATTERHORN & CRITICS-II (presented today)! Japanese EPOC2031 Ph2: TNT for resectable GEJ -FLOT + pembro + short course RT (25 Gy/5fx) -1 endpt: EFS -Key 2nd endpts: organ pres & QOL.”
“Great discussion by Dr. Daniel Lin. For Herizon study, agree with outdated comparator arm is big limitation so big question now is who would actually use it if our current SOC is not truly represented.”
“We did sneak in some NET time at GI26.
Hoping ASCO will see the importance of focusing more on rarer cancers like Neuroendocrine tumors. It would mean so much for our field and for the patients that we care for.”
“Outstanding presentation by Maheswari Senthil on gastric peritoneal carcinomatosis!Thrilled to now offer eligible patients the STOPGAP II trial (EA 2234)—a randomized study clarifying the role of cytoreductive surgery ± IP chemo in this challenging population. ”
“Is HER2 tx the answer for HER2 mutated non-amp GI cancers? Check out our GI26 abstract. Coexisting HER2 mutations may have an impact on HER2 tx efficacy in amp non-esophagogastric GI cancers. Also, congrats to my amazing mentor Sunnie Kim
on chairing a great session!”
“I wish I’d taken more computing classes back in the day to have a stronger foundation now to understand AI and its impact in oncology. That in mind, thanks ASCO GI26 for the “Intersections” session underway *RIGHT NOW * on its use in GI cancers!”
Sharlene Gill, MD, MPH, MBA, FASCO:
“GI26 ASCO
HERIZON GEA01 Congrats Dr Elimova UHN
Zanidatamab – HER bispecific N=914, 1L HER2+ CT+ traz v CT + zani v CT + zani + tisle PD1 CT – CAPOX or cisp/5FU mOS 26.4m triplet vs CT+tras 19.2m, HR 0.72, p=0.0043 w sig PFS benefit. PFS CT + zani 12.4m v CT + tras 8.1m, HR 0.85, p<0.0001. OS pending. Diarrhea is an issue (prophylactic loperamide needed) Impressive OS – current SOC is triplet per KN811 2L GA4 with zani ongoing!”
More posts about ASCO GI on OncoDaily
Written by Nare Hovhannisyan, MD